Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Apr 5;73(5):854-866.
doi: 10.1136/gutjnl-2023-329963.

Fibrosis in IBD: from pathogenesis to therapeutic targets

Florian Rieder  1 , Pranab K Mukherjee  2 , William J Massey  2 , Yan Wang  2 , Claudio Fiocchi  2
Affiliations
Review

Fibrosis in IBD: from pathogenesis to therapeutic targets

Florian Rieder et al. Gut. .

Abstract

Background: Intestinal fibrosis resulting in stricture formation and obstruction in Crohn's disease (CD) and increased wall stiffness leading to symptoms in ulcerative colitis (UC) is among the largest unmet needs in inflammatory bowel disease (IBD). Fibrosis is caused by a multifactorial and complex process involving immune and non-immune cells, their soluble mediators and exposure to luminal contents, such as microbiota and environmental factors. To date, no antifibrotic therapy is available. Some progress has been made in creating consensus definitions and measurements to quantify stricture morphology for clinical practice and trials, but approaches to determine the degree of fibrosis within a stricture are still lacking.

Objective: We herein describe the current state of stricture pathogenesis, measuring tools and clinical trial endpoints development.

Design: Data presented and discussed in this review derive from the past and recent literature and the authors' own research and experience.

Results and conclusions: Significant progress has been made in better understanding the pathogenesis of fibrosis, but additional studies and preclinical developments are needed to define specific therapeutic targets.

Keywords: fibrosis; inflammatory bowel disease; myofibroblasts.

PubMed Disclaimer

Conflict of interest statement

Competing interests: PM, WJM and YW have no conflict of interest. CF received speaker fees from UCB, Genentech, Sandoz, Janssen and he is consultant for Athos Therapeutics. FR is consultant to Agomab, Allergan, AbbVie, Boehringer-Ingelheim, Celgene, Cowen, Genentech, Gilead, Gossamer, Guidepoint, Helmsley, Index Pharma, Jansen, Koutif, Metacrine, Morphic, Pfizer, Pliant, Prometheus Biosciences, Receptos, RedX, Roche, Samsung, Takeda, Techlab, Thetis, UCB, 89Bio.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Louis E, Collard A, Oger AF, Degroote E, Aboul Nasr El Yafi FA, Belaiche J. Behaviour of Crohn’s disease according to the Vienna classification: changing pattern over the course of the disease. Gut 2001;49:777–82. - PMC - PubMed
    1. Cosnes J, Bourrier A, Nion-Larmurier I, Sokol H, Beaugerie L, Seksik P. Factors affecting outcomes in Crohn’s disease over 15 years. Gut 2012;61:1140–5. - PMC - PubMed
    1. Rieder F, Fiocchi C, Rogler G. Mechanisms, Management, and Treatment of Fibrosis in Patients With Inflammatory Bowel Diseases. Gastroenterology 2017;152:340–50 e6. - PMC - PubMed
    1. Yoo JH, Holubar S, Rieder F. Fibrostenotic strictures in Crohn’s disease. Intest Res 2020. - PMC - PubMed
    1. Gordon IO, Agrawal N, Willis E, Goldblum JR, Lopez R, Allende D, et al. Fibrosis in ulcerative colitis is directly linked to severity and chronicity of mucosal inflammation. Aliment Pharmacol Ther 2018;47:922–39. - PMC - PubMed

Publication types

LinkOut - more resources